Barriers to hepatitis C treatment
- PMID: 22212587
- PMCID: PMC3955982
- DOI: 10.1111/j.1478-3231.2011.02706.x
Barriers to hepatitis C treatment
Abstract
Despite the availability of highly effective therapy for hepatitis C virus (HCV) infection, few patients receive treatment. Barriers arising at multiple levels, from diagnosis to specialist referral, may impede the delivery of hepatitis C care. At the patient level, lack of awareness, fear of side effects, poor adherence and comorbid conditions may prevent treatment. For providers, limited knowledge, lack of availability and communication difficulties may be problematic. At the government and payer level, a lack of promotion, surveillance and funding may interfere. Each of these barriers needs to be addressed if wider implementation of antiviral therapy is to be achieved.
© 2012 John Wiley & Sons A/S.
Figures
Similar articles
-
Boceprevir for chronic HCV genotype 1 infection.N Engl J Med. 2011 Jul 14;365(2):176; author reply 177-8. doi: 10.1056/NEJMc1105515. N Engl J Med. 2011. PMID: 21751914 No abstract available.
-
The future for the treatment of genotype 4 chronic hepatitis C.Liver Int. 2012 Feb;32 Suppl 1:146-50. doi: 10.1111/j.1478-3231.2011.02704.x. Liver Int. 2012. PMID: 22212586 Review.
-
Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'?Liver Int. 2012 Feb;32 Suppl 1:61-3. doi: 10.1111/j.1478-3231.2011.02717.x. Liver Int. 2012. PMID: 22212574 Review.
-
Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?Liver Int. 2012 Feb;32 Suppl 1:54-60. doi: 10.1111/j.1478-3231.2011.02718.x. Liver Int. 2012. PMID: 22212573 Review.
-
A new era of hepatitis C therapy begins.N Engl J Med. 2011 Mar 31;364(13):1272-4. doi: 10.1056/NEJMe1100829. N Engl J Med. 2011. PMID: 21449791 No abstract available.
Cited by
-
Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response.Liver Int. 2013 Aug;33(7):999-1007. doi: 10.1111/liv.12150. Epub 2013 Mar 20. Liver Int. 2013. PMID: 23509897 Free PMC article.
-
Therapeutic approach to the treatment-naive patient with hepatitis C virus genotype 1 infection: a step-by-step approach.Clin Infect Dis. 2012 Nov;55(9):1236-41. doi: 10.1093/cid/cis628. Epub 2012 Jul 26. Clin Infect Dis. 2012. PMID: 22843782 Free PMC article. Review.
-
Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study.BMC Gastroenterol. 2016 Apr 4;16:45. doi: 10.1186/s12876-016-0438-z. BMC Gastroenterol. 2016. PMID: 27044402 Free PMC article.
-
A Simplified Algorithm for the Management of Hepatitis C Infection.Gastroenterol Hepatol (N Y). 2019 May;15(5 Suppl 3):1-12. Gastroenterol Hepatol (N Y). 2019. PMID: 31641341 Free PMC article.
-
Animal Models of Hepatitis C Virus Infection.Cold Spring Harb Perspect Med. 2020 May 1;10(5):a036970. doi: 10.1101/cshperspect.a036970. Cold Spring Harb Perspect Med. 2020. PMID: 31843875 Free PMC article. Review.
References
-
- Serologic findings with hepatitis B in hemophilia. . N Engl J Med. 1978;299(16):898–900. - PubMed
-
- Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–965. - PubMed
-
- Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975–982. - PubMed
-
- Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011 Jun 23;364(25):2405–2416. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical